Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients

Chronic Kidney Disease-Mineral and Bone Disorder Clinical Trial

Official title:

Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05399251
• Other study ID #: ERC # 2020-3295-14097
• Status: Completed
• Start date: January 1, 2015
• Est. completion date: December 30, 2021

Study information

• Verified date: May 2022
• Source: Aga Khan University Hospital, Pakistan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This cross-sectional study was conducted, including those subjects tested for 1,25(OH)2D during Jan 2015-Dec 2021. Estimated glomerular filtration rate (eGFR) was calculated and subjects were classified into chronic kidney disease (CKD) stages. Associations between biochemical marker, calcium, phosphorus, magnesium, alkaline phosphatase, 1,25(OH)2D and CKD stages was determined.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1553
• Est. completion date: December 30, 2021
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Data of serum 1,25(OH)2D available

Exclusion Criteria:

• Serum1,25(OH)2D is not available

Related Conditions & MeSH terms

• Bone Diseases
• Chronic Kidney Disease-Mineral and Bone Disorder
• Kidney Diseases
• Renal Insufficiency
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aga Khan University Hospital, Pakistan

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	concentration of serum 1,25 dihydroxy vitamin D in U/L in five stages of chronic kidney disease	In CKD, 1-alfa-hydroxylase activity in the kidneys is reduced, leading to decreases in the level of the activated form of vitamin D (1,25- dihydroxy vitamin D), resulting in secondary hyperparathyroidism and bone disease. This study aimed to determine the concentration of 1,25 dihydroxy vitamin D in different stages of CKD.	7 year
Primary	concentration of serum calcium in mg/dl in five stages of chronic kidney disease	in renal tubules, 1,25- dihydroxy vitamin D increase reabsorption of calcium from renal filtrate and thus stabilize blood calcium levels. in CKD, with deterioration of kidney function, stage V, the levels of calcium drops resulting in hypocalcemia.	7 years